AstraZeneca said a closely watched experimental cancer drug failed in a clinical trial when used on its own to treat mesothelioma, a rare lung and abdominal cancer, but it remained confident the drug had a role to play in combination treatments. Tremelimumab failed to meet the primary endpoint of improving overall survival in hard-to-treat mesothelioma patients, the drugmaker said on Monday.
